Home » Topics » Musculoskeletal, BioWorld Science

Musculoskeletal, BioWorld Science
RSS

Xencor begins phase Ib/IIa trial of XmAb-5871

Feb. 14, 2013

ALX-0061 demonstrates good efficacy and safety in RA patients

Feb. 14, 2013

Infinity Pharmaceuticals and Intellikine patent new PI3K inhibitors

Feb. 13, 2013

UCB and Amgen decide not to pursue romosozumab program in fracture healing

Feb. 12, 2013

Merck & Co. prepares new BTK inhibitors

Feb. 11, 2013

Eli Lilly discontinues clinical trials of tabalumab in RA

Feb. 8, 2013

Seikagaku begins phase II trial for SI-613 in Japan

Feb. 7, 2013

GSK to advance GSK-2586184 into phase II studies

Feb. 7, 2013

AOD-9604 shows promise in rabbit model of osteoarthritis

Feb. 6, 2013

Novel candidate JNK1 inhibitors patented

Feb. 5, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...